Addex Therapeutics (ADXN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Addex Therapeutics (ADXN) is a CH-listed Healthcare company in Biotechnology with a market capitalization of $4M, trading at $5.92 on the NASDAQ. This SniperIQ fundamentals page covers Addex Therapeutics's valuation, profitability (net margin -7775.2%), revenue (CHF 29,972 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Addex Therapeutics's market cap?
Addex Therapeutics (ADXN) has a market capitalization of approximately $4M, trading at $5.92 on the NASDAQ. Market cap moves with the live share price.
What is Addex Therapeutics's P/E ratio?
Addex Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Addex Therapeutics?
Addex Therapeutics runs a net profit margin of -7775.2%, a gross margin of 84.3%, and an operating margin of -2999.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Addex Therapeutics generate?
Addex Therapeutics reported revenue of CHF 29,972 for fiscal year 2025, with net income of -CHF 7M and earnings per share (EPS) of -6.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Addex Therapeutics pay a dividend?
Addex Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Addex Therapeutics financially healthy?
Addex Therapeutics carries a debt-to-equity ratio of 0.03x and a current ratio of 0.97x, with a market beta of 1.99. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Addex Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Addex Therapeutics (ADXN) the key facts are: market cap $4M, revenue CHF 29,972, 52-week range 5.41-12.05. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Addex Therapeutics's full fundamentals live
Get Addex Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.